Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: The M. D. Anderson Cancer Center experience

Cancer

Volumn 103, Issue 10, 2005, Pages 2091-2098

  Escalón, Maricer P ^a   Liu, Nina S ^a   Yang, Ying ^a   Hess, Mark ^a   Walker, Pamela L ^a   Smith, Terry L ^a   Dang, Nam H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anaplastic large cell lymphoma; International prognostic index; Non Hodgkin lymphoma; Peripheral T cell lymphoma; Prognostic factors; T cell lymphoma; Tumor score

Indexed keywords

BETA 2 MICROGLOBULIN; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; LACTATE DEHYDROGENASE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; B CELL LYMPHOMA; ELECTROCORTICOGRAPHY; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; T CELL LYMPHOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, LARGE-CELL; LYMPHOMA, T-CELL; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 18044383718     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20999     Document Type: Article

References (22)

1. Melnyk A, Rodriguez A, Pugh WC, et al. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood. 1997:89:4514-4520.
2. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood. 1998;92:76-82.
3. Arrowsmith ER, Macon WR, Kinney MC, et al. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymphoma. 2003;44:241-249.
4. Cheng AL, Chen YC, Wang CH, et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades-should peripheral T-cell lymphoma be considered separately? J Clin Oncol. 1989;7:725-731.
5. Kwak LW, Wilson M, Weiss LM, et al. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. J Clin Oncol. 1991;9:1426-1431.
6. Armitage JO, Vose JM, Linder J, et al. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1989;7:1783-1790.
7. Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol. 1990;1:45-50.
8. Grogan TM, Fielder K, Rangel C, et al. Peripheral T-cell lymphoma: aggressive disease with heterogeneous immunotypes. Am J Clin Pathol. 1985;83:279-288.
9. Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project. Ann Oncol. 2002;13:140-149.
10. Weisenburger DD, Anderson JR, Diebold J, et al. Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project. Am J Hematol. 2001;67:172-178.
11. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med. 1993;329:987-994.
12. Rodriguez J, Cabanillas F, McLaughlin P, et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the "tumor score". Ann Oncol. 1992;3:711-777.
13. Rodriguez J, Caballero MD, Gutierrez A, et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica, 2003;88:1372-1377.
14. Rodriguez J, Munsell M, Yazji S, et al. Impact of high-dose chemotherapy onperipheral T-cell lymphomas. J Clin Oncol. 2001;19:3766-3770.
15. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971;31:1860-1861.
16. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
17. Tilly H, Gaulard P, Lepage E, et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood. 1997;90:3727-3734.
18. Longo G, Fiorani C, Sacchi S, et al. Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per lo Studio dei Linfomi (GISL). Haematologica. 1999;84:425-430.
19. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol. 2000;53:445-450.
20. Reiser M, Josting A, Soltani M, et al. T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma. 2002;43:805-811.
21. ten Berge RL, de Bruin PC, Oudejans JJ, et al. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology. 2003;43:462-469.
22. George DH, Scheithauer BW, Aker FV, et al. Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression. Am J Surg Pathol. 2003;27:487-493.